5 assets in Undifferentiated Pleomorphic Sarcoma

Therapeutic assets addressing Undifferentiated Pleomorphic Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bbi-355 Undifferentiated Pleomorphic Sarcoma	Boundless Bio, Inc.	P1	CC (43)
Bbi-825 Undifferentiated Pleomorphic Sarcoma	Boundless Bio, Inc.	P1	CC (43)
Futibatinib Undifferentiated Pleomorphic Sarcoma	Boundless Bio, Inc.	P1	CC (43)
okn4395 Undifferentiated Pleomorphic Sarcoma	Epkin	P1	CC (43)
Pembrolizumab Undifferentiated Pleomorphic Sarcoma	Epkin	P1	CC (43)